AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression ...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III ...
Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the noninferiority bar against LHRH agonists.
After neoadjuvant breast cancer treatment, axillary radiotherapy may offer an effective alternative to axillary lymph node dissection.
RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR ...
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
US Food and Drug Administration (FDA) officials credited recent advancements in regulatory science and flexibilities with ...
A clinical trial led by University of Auckland researchers found that high-intensity therapy for patients begun within two ...
The main advantage of proton therapy is its precision. Protons deposit most of their energy directly in the tumor with little ...
The U.S. Food and Drug Administration (FDA) on Friday concluded that Replimmune Group Inc. REPL Biologics License Application ...
CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for ...
First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results